Clinical trial · no report yet · Phase 2/Phase 3
CIRCULATE-US
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- NCT05174169 ↗
- Recruiting
- NRG Oncology
- 116 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 46 | |
| X threads | 41 | |
| Podcasts | 29 |
The trial
ClinicalTrials.gov- Official title
- Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- Phase
- Phase 2/Phase 3
- Status
- Recruiting
- Conditions
- Stage III Colon Cancer
- Interventions
- Signatera test; mFOLFOX6 3-6 month; CAPOX 3 month; mFOLFIRINOX; mFOLFOX6 6 month; CAPOX 6 month
- Arms
- Cohort A - Arm 1 (ctDNA-ve) · Active comparator
- Cohort A - Arm 2 (ctDNA-ve) · Experimental
- Cohort B - Arm 3 (ctDNA+ve) · Active comparator
- Cohort B - Arm 4 (ctDNA+ve) · Experimental
- Enrollment
- 1,912 (estimated)
- Primary outcomes
- ctDNA positive status (TTPos)
- Disease-Free Survival (DFS)
- Sponsor
- NRG Oncology with Natera, Inc., National Cancer Institute (NCI)
- Start
- Jul 8, 2022
- Primary completion
- Mar 10, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT05174169 · updated Sep 2, 2026